Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Amelia Zelnak"'
Autor:
Stacy Moulder, Das Purkayastha, Hope S. Rugo, Cynthia Ma, Lowell Hart, Sibel Blau, Tara Sanft, Meghan Karuturi, Denise A. Yardley, Amelia Zelnak, Amy S. Clark, Angela DeMichele, Sara A. Hurvitz, Aditya Bardia
Supplementary Tables
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f79162e403f52cd2827f8f30f5dab00
https://doi.org/10.1158/1078-0432.22480703.v1
https://doi.org/10.1158/1078-0432.22480703.v1
Autor:
Stacy Moulder, Das Purkayastha, Hope S. Rugo, Cynthia Ma, Lowell Hart, Sibel Blau, Tara Sanft, Meghan Karuturi, Denise A. Yardley, Amelia Zelnak, Amy S. Clark, Angela DeMichele, Sara A. Hurvitz, Aditya Bardia
Raw ctDNA data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5502b491810b2c3807132692ff9904ac
https://doi.org/10.1158/1078-0432.22480697
https://doi.org/10.1158/1078-0432.22480697
Autor:
Stacy Moulder, Das Purkayastha, Hope S. Rugo, Cynthia Ma, Lowell Hart, Sibel Blau, Tara Sanft, Meghan Karuturi, Denise A. Yardley, Amelia Zelnak, Amy S. Clark, Angela DeMichele, Sara A. Hurvitz, Aditya Bardia
Purpose:Standard-of-care treatment for metastatic hormone receptor–positive (HR+), HER2-negative (HER2−) breast cancer includes endocrine therapy (ET) combined with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i). Optimal treatment after progre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f70b18e05e6e18e7fadac82839c4c0a
https://doi.org/10.1158/1078-0432.c.6530513
https://doi.org/10.1158/1078-0432.c.6530513
Autor:
Stacy Moulder, Das Purkayastha, Hope S. Rugo, Cynthia Ma, Lowell Hart, Sibel Blau, Tara Sanft, Meghan Karuturi, Denise A. Yardley, Amelia Zelnak, Amy S. Clark, Angela DeMichele, Sara A. Hurvitz, Aditya Bardia
Supplemental Figure 1. ER, PI3K/mTOR, and CDK4/6 Pathways in HR+ Breast Cancer Supplemental Figure 2. Median Ctrough From Cycle 1 Day 15 in Cohorts A and B. Supplemental Figure 3. Time to Progression or Time on Study Treatment Supplemental Figure 4.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16a86d3037488025a711951040a9c8f7
https://doi.org/10.1158/1078-0432.22480706.v1
https://doi.org/10.1158/1078-0432.22480706.v1
Autor:
Nancy U. Lin, Rashmi K. Murthy, Vandana Abramson, Carey Anders, Thomas Bachelot, Philippe L. Bedard, Virginia Borges, David Cameron, Lisa A. Carey, A. Jo Chien, Giuseppe Curigliano, Michael P. DiGiovanna, Karen Gelmon, Gabriel Hortobagyi, Sara A. Hurvitz, Ian Krop, Sherene Loi, Sibylle Loibl, Volkmar Mueller, Mafalda Oliveira, Elisavet Paplomata, Mark Pegram, Dennis Slamon, Amelia Zelnak, Jorge Ramos, Wentao Feng, Eric Winer
Publikováno v:
Scientia
U. Lin, N, K. Murthy, R, Abramson, V, Anders, C, Bachelot, T, L. Bedard, P, Borges, V, Cameron, D A, A. Carey, L, Chien, J, Curigliano, G, P. Di Giovanna, M, Gelmon, K, Hortobagyi, G, A. Hurvitz, S, Krop, I, Loi, S, Loibl, S, Mueller, V, Oliveira, M, Paplomata, E, Pegram, M, Slamon, D, Zelnak, A, Ramos, J, Feng, W & Winer, E 2022, ' Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain MetastasesUpdated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial ', JAMA Oncology . https://doi.org/10.1001/jamaoncol.2022.5610
U. Lin, N, K. Murthy, R, Abramson, V, Anders, C, Bachelot, T, L. Bedard, P, Borges, V, Cameron, D A, A. Carey, L, Chien, J, Curigliano, G, P. Di Giovanna, M, Gelmon, K, Hortobagyi, G, A. Hurvitz, S, Krop, I, Loi, S, Loibl, S, Mueller, V, Oliveira, M, Paplomata, E, Pegram, M, Slamon, D, Zelnak, A, Ramos, J, Feng, W & Winer, E 2022, ' Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain MetastasesUpdated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial ', JAMA Oncology . https://doi.org/10.1001/jamaoncol.2022.5610
ImportanceIt is estimated that up to 50% of patients with ERBB2 (HER2)-positive metastatic breast cancer (MBC) will develop brain metastases (BMs), which is associated with poor prognosis. Previous reports of the HER2CLIMB trial have demonstrated tha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f800399cc04de7baef3960b16afc0f9b
https://hdl.handle.net/11351/9527
https://hdl.handle.net/11351/9527
Autor:
Caitlin Taylor, Jane Meisel, Aimee J. Foreman, Christy Russell, Dipankar Bandyopadhyay, Xiaoyan Deng, Lisa Floyd, Amelia Zelnak, Harry Bear, Ruth O’Regan
Purpose The role of neoadjuvant endocrine therapy in the treatment of patients with early-stage, hormone receptor-positive (HR +) breast cancer is not well defined. Tools to better determine which patients may benefit from neoadjuvant endocrine thera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83b8a1128726571c675738adb05ddd35
https://doi.org/10.21203/rs.3.rs-2228265/v1
https://doi.org/10.21203/rs.3.rs-2228265/v1
Autor:
Lisa A. Carey, Amelia Zelnak, Hope S. Rugo, Florence Dalenc, Rita Nanda, Michael Danso, Mahasti Saghatchian, Kevin Kalinsky, Nelly Firmin, Manuel Ruiz-Borrego, Anne Favret, Jun Sun, Lee Schwartzberg, Christie Hilton, Coral Omene, Robyn Young, Sara A. Hurvitz, Eliza Harting, See Phan, Aditya Bardia
Publikováno v:
Cancer Research. 82:P5-16
Background: Black women have higher incidence rates of TNBC and may experience worse clinical outcomes compared with White women with TNBC, due to disparities, comorbidities, or differences in TNBC biology (Dietze EG, et al. Nat Rev Cancer. 2015;15:2
Autor:
Martin Olivo, Priyanka Sharma, Sara A. Hurvitz, Javier Cortes, Quan Hong, Eva Maria Ciruelos Gil, Sara M. Tolaney, Erika Hamiltion, Kevin Kalinsky, Joyce O'Shaughnessy, Philippe Aftimos, Loretta M. Itri, Linda T. Vahdat, Delphine Loirat, Lisa A. Carey, Véronique Diéras, Michaela Tsai, Tiffany A. Traina, Amelia Zelnak, David M. Goldenberg, Florence Dalenc, Sabela Recalde, Hope S. Rugo, Kevin Punie, Sagar Sardesai, Mafalda Oliveira, Aditya Bardia
Publikováno v:
Cancer Research. 81:GS3-06
Background: Trophoblast cell-surface antigen-2 (Trop-2) is highly expressed in many epithelial tumors, including triple-negative breast cancer (TNBC). Sacituzumab govitecan (SG) is an antibody-drug conjugate composed of an anti-Trop-2 antibody couple
Autor:
Rashmi Krishna Murthy, Amelia Zelnak, Giuseppe Curigliano, Carey K. Anders, Elisavet Paplomata, Mafalda Oliveira, Eric P. Winer, Virginia F. Borges, Karen A. Gelmon, Alison Conlin, Xuebei An, Michael DiGiovanna, Sibylle Loibl, Alicia Okines, Sara A. Hurvitz, Ruth O'Regan, Philippe L. Bedard, Andrew M Wardley, Lisa A. Carey, Thomas Bachelot, Jo Al Mayor, David Cameron, A. Jo Chien, Nan Lin, Sherene Loi, Vandana G. Abramson, Suzanne McGoldrick, Erika Hamilton, Volkmar Mueller
Publikováno v:
Journal of Clinical Oncology
Scientia
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 38, iss 23
Lin, N U, Borges, V, Anders, C, Murthy, R K, Paplomata, E, Hamilton, E, Hurvitz, S, Loi, S, Okines, A, Abramson, V, Bedard, P L, Oliveira, M, Mueller, V, Zelnak, A, Digiovanna, M P, Bachelot, T, Chien, A J, O’regan, R, Wardley, A, Conlin, A, Cameron, D, Carey, L, Curigliano, G, Gelmon, K, Loibl, S, Mayor, J, Mcgoldrick, S, An, X & Winer, E P 2020, ' Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial ', Journal of Clinical Oncology, pp. JCO.20.00775 . https://doi.org/10.1200/JCO.20.00775, https://doi.org/10.1200/JCO.20.00775
BASE-Bielefeld Academic Search Engine
Scientia
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 38, iss 23
Lin, N U, Borges, V, Anders, C, Murthy, R K, Paplomata, E, Hamilton, E, Hurvitz, S, Loi, S, Okines, A, Abramson, V, Bedard, P L, Oliveira, M, Mueller, V, Zelnak, A, Digiovanna, M P, Bachelot, T, Chien, A J, O’regan, R, Wardley, A, Conlin, A, Cameron, D, Carey, L, Curigliano, G, Gelmon, K, Loibl, S, Mayor, J, Mcgoldrick, S, An, X & Winer, E P 2020, ' Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial ', Journal of Clinical Oncology, pp. JCO.20.00775 . https://doi.org/10.1200/JCO.20.00775, https://doi.org/10.1200/JCO.20.00775
BASE-Bielefeld Academic Search Engine
PURPOSE In the HER2CLIMB study, patients with human epidermal growth factor receptor 2 (HER2)–positive breast cancer with brain metastases (BMs) showed statistically significant improvement in progression-free survival (PFS) with tucatinib. We desc
Autor:
Kevin Kalinsky, Javier Cortes, E.C. Gil, Véronique Diéras, Michaela Tsai, Tiffany A. Traina, Lisa A. Carey, L. Vahdat, Florence Dalenc, Philippe Aftimos, Erika Hamilton, Sara A. Hurvitz, Sara M. Tolaney, S. Recalde, L.M. Itri, Priyanka Sharma, Joyce O'Shaughnessy, Hope S. Rugo, Martin Olivo, Mafalda Oliveira, Delphine Loirat, Kevin Punie, Q. Hong, Amelia Zelnak, David M. Goldenberg, Sagar Sardesai, Aditya Bardia
Publikováno v:
Annals of oncology
Scientia
Scientia
Background: The pivotal phase III ASCENT trial demonstrated improved survival outcomes associated with sacituzumab govitecan (SG), an anti-trophoblast cell-surface antigen 2 (anti-Trop-2) antibody-drug conjugate linked with the topoisomerase-inhibito
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7674f8ee6f826048de62dac913e752f3
https://lirias.kuleuven.be/handle/20.500.12942/686442
https://lirias.kuleuven.be/handle/20.500.12942/686442